Pembrolizumab in Ultramutated and Hypermutated Endometrial Cancer

Model scores of the 29,894 trials active now.

Model score 22% for any early termination, 11% for termination due to slow enrollment. Past trials like this one (phase, sponsor type and disease area, started 2008–2016) ended terminated 26% of the time (3,728 trials).

Finished trial that started in 2015 or later: the model never saw it during training.

Cumulative chance of ending terminated (red) or completed (green) by each year from its start; it actually ended on 2024-07-17. The rest of the way to 100% is still running.

From the competing-risks survival model (termination vs completion, still-running trials censored), fit to trials that started 2008–2014 and recalibrated to termination rates over 2022–2024, since termination has become more common. Checked on past years, it still ran a little low when the rise continued.

• Wording of the registration (title, summary, criteria) (raises risk) · Wording Phrases that raised it: patients mustradiationcellcancercarcinoma of
  Phrases that lowered it: psoriasissystemictopicalpatients whocorticosteroids
• Accepts healthy volunteers: No (raises risk) · Who can join
• Phase: 2 (raises risk) · Design
• Maximum age: 100 (lowers risk) · Who can join
• Sponsor's past termination rate: 10.1% (raises risk) · Sponsor's track record
• Drug's FAERS reports with a death: 33.8% (raises risk) · Drug's FDA history
• Disease area, cancer: Yes (raises risk) · Disease area
• Trials the sponsor started in the prior 2 years: 116 (lowers risk) · Sponsor's track record
• Has a data monitoring committee: Yes (raises risk) · Design
• Design: single group (raises risk) · Design
• Sponsor type: academic or other (raises risk) · Sponsor's track record
• Sponsor's past trials: 447 (lowers risk) · Sponsor's track record
• Primary purpose: treatment (raises risk) · Design
• Minimum age: 18 (raises risk) · Who can join
• Collaborators: 1 (raises risk) · Design
• Drug's FAERS reports marked serious: 78.3% (lowers risk) · Drug's FDA history
• Responsible party: sponsor (lowers risk) · Design
• Drug's FAERS reports before start: 3207 (raises risk) · Drug's FDA history
• Number of arms: 1 (raises risk) · Design

Every input that moved this score, largest first: SHAP contributions in log-odds, red raising risk and green lowering it. They describe the model, not causes of termination. Phrases are traced from the text features back to this registration's words, approximately.

• Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma NCT02428192 · started 2015 · scored riskier than 70% of active trials completed
• Pembro/Carbo/Taxol in Endometrial Cancer NCT02549209 · started 2017 · scored riskier than 99% of active trials completed
• Neo-adjuvant Pembrolizumab in dMMR/ POLE-EDM Uterine Cancer Patients: a Feasibility Study NCT04262089 · started 2020 · scored riskier than 54% of active trials completed
• Phase II Trial of Magrolimab and Cetuximab With Pembrolizumab or Docetaxel for Recurrent/Metastatic Head Neck Squamous Cell Carcinoma NCT06046482 · started 2023 · scored riskier than 98% of active trials terminated
• Pembrolizumab, Paclitaxel, and Carboplatin in Patients With Advanced Stage Epithelial Ovarian Cancer (EOC). NCT02834975 · started 2016 · scored riskier than 98% of active trials terminated

Closest by meaning of the registration text (PubMedBERT embeddings), among finished trials. How they ended is context, not an input to this trial's score.